Novel agents in multiple myeloma: considering toxicity and side effects
Revisiting clinical trial design – more adaptability in Phase I – III?
Elihu H. Estey
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
MPN Landmark studies: looking at the disparities in perceptions of disease and treatment preferences
AL amyloidosis and a critical, early diagnosis